|Trade names||Stugeron, Stunarone, Cinarin|
|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||3–4 h|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||368.524 g·mol−1|
|3D model (JSmol)|
Cinnarizine is an antihistamine and calcium channel blocker of the diphenylmethylpiperazine group. It is prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease.
Cinnarizine was first synthesized as R1575 by Janssen Pharmaceutica in 1955. The nonproprietary name is derived from the cinnamyl substituent on one of the nitrogen atoms, combined with the generic ending "-rizine" for "antihistaminics/cerebral (or peripheral) vasodilators". It is not available in the United States or Canada. It has also been cited as one of the most used drugs for seasickness within the British Royal Navy.
In fact, it is one of only a select few drugs that has shown a beneficial effect in the chronic treatment of the vertigo and tinnitus, associated with Meniere's disease. However, due to increased levels of drowsiness caused by the medication, it is generally of limited use in pilots and aircrew who must be dependably alert. In a clinical study (n=181), treatment with cinnarizine reduced the occurrence of moderate vertigo experience by 65.8% and extreme vertigo by 89.8%.
It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus by limiting the activity of the vestibular hair cells which send signals about movement. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness could be a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception, but the true evolutionary reason for this malady is currently unknown.
When prescribed for balance problems and vertigo, cinnarizine is typically taken two or three times daily depending on the amount of each dose and when used to treat motion sickness, the pill is taken at least two hours before travelling and then again every four hours during travel. However, a recent 2012 study comparing the effects of cinnarizine to transdermal scopolamine for the treatment of seasickness, concluded that scopolamine was reported as significantly more effective and as having fewer adverse side effects than cinnarizine. This led to the conclusion that transdermal scopolamine is likely a better option for the treatment of motion sickness in naval crew and other sea travelers.
Beyond an anti-vertigo treatment, cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockade), which happen mostly in brain and the fact that it is also used as a labyrinthine sedative. Cinnarizine inhibits the flow of calcium into red blood cells, which increases the elasticity of the cell wall, thereby increasing their flexibility and making the blood less viscous. This allows the blood to travel more efficiently and effectively through narrowed vessels in order to bring oxygen to damaged tissue. It is also effectively combined with other nootropics, primarily piracetam; in such combination each drug potentiates the other in boosting brain oxygen supply. An animal study comparing the effectiveness of cinnarizine and flunarizine (a derivative of cinnarizine that is 2.5-15 times stronger  for treatment of transient global cerebral ischemia, it was found that cinnarizine helped to improve the functional abnormalities of ischemia, but did not help with damage to the neurons. Flunarizine, on the other hand, offered more neuronal protection, but was less effective in treating subsequent behavioral changes.
Additionally, cinnarizine can be used in scuba divers without an increased risk of central nervous system oxygen toxicity which can result in seizures, and is a high risk in closed-circuit oxygen diving. This is also relevant to divers who could potentially have to undergo hypobaric decompression therapy, which uses high oxygen pressure and could also be affected by any cinnarizine-induced CNS oxygen toxicity risk. However, cinnarizine does not heighten toxicity risk, and in fact, evidence even seems to suggest that cinnarizine may be beneficial in helping delay O2 toxicity in the central nervous system. There is also evidence that cinnarizine may be used as an effective anti-asthma medication when taken regularly.
Side effects experienced while taking cinnarizine range from the mild to the quite severe. Possible side effects include drowsiness, sweating, dry mouth, headache, skin problems, lethargy, gastrointestinal irritation, hypersensitivity reactions, as well as movement problems/muscle rigidity, and tremor. Because cinnarizine can cause drowsiness and blurred vision, it is important that users make sure their reactions are normal before driving, operating machinery, or doing any other jobs which could be dangerous if they are not fully alert or able to see well.
Cinnarizine is also known to cause acute and chronic parkinsonism due to its affinity for D2 receptors, which strongly counter-suggests its actual usefulness for improving neurohealth. Cinnarizine's antagonistic effects of D2 dopamine receptors in the striatum leads to symptoms of depression, tremor, muscle rigidity, tardive dyskinesia, and akathisia, which are characterized as Drug-Induced Parkinson's disease and is the second leading cause of Parkinson's. Evidence suggests that it is one of the metabolites of cinnarizine, C-2, that has an active role in contributing to the development of drug-induced Parkinson's. It is also of note that an estimated 17 of 100 new Parkinson's cases are linked to administration of either cinnarizine or Flunarizine, making cinnarizine and drug-induced Parkinson's a serious issue. Those people especially at risk are elderly patients, in particular women, and patients who have been taking the drug for a longer amount of time. There is also evidence that suggests that patients with a family history of Parkinson's, or a genetic predisposition to the disease are more likely to develop the drug induced form of this disease as a result of cinnarizine treatment.
In addition to antagonizing D2 receptors, treatment with cinnarizine has also been shown to lead to reduced presynaptic dopamine and serotonin, as well as alterations in vesicular transport of dopamine. Terland et al. have shown that chronic treatment with cinnarizine builds the drug concentrations high enough that they interfere with the proton electrochemical gradient necessary for packaging dopamine into vesicles. Cinnarizine, pKa = 7.4, acts as a protonophore, which prevents the MgATP-dependent production of the electrochemical gradient crucial to the transport and storage of dopamine into vesicles, and thereby lowers the levels of dopamine in the basal ganglia neurons and leads to the Parkinson's symptoms.
Additionally, several cases of pediatric and adult cinnarizine overdose have been reported, with effects including a range of symptoms such as somnolence, coma, vomiting, hypotonia, stupor, and convulsions. The cognitive complications likely result from the antihistaminic effects of cinnarizine, while the motor effects are a product of the antidopaminergic properties. In cases of overdose, the patient should be brought to and observed in a hospital for potential neurological complications.
Cinnarizine is most commonly taken orally, in tablet form, with frequency and amount of dosage varying depending on the reason for taking the medication. Once ingested, the substance is absorbed quite rapidly and reaches a peak plasma concentration in 1–3 hours post-administration. Cmax, the maximum level of the drug in the tested area (typically blood plasma), has been measured to be 275 +/- 36 ng/mL, where tmax, the amount of time that the drug is present at the max amount in the blood, was 3.0 +/-0.5 hours. AUC∞, (the area under the curve extrapolated to infinity) which can be used to estimate bioavailability, was 4437 +/- 948 (ng.h/mL). The half-life elimination varies from 3.4–60 hours, depending on age. However, the mean terminal half-life elimination for young volunteer subjects administered 75 mg cinnarizine, was found to be 23.6 +/- 3.2 hours.
A study that administered 75 mg doses of cinnarizine, twice a day for twelve days, to healthy volunteers, observed that cinnarizine did build up in the body, with a steady-state accumulation factor of 2.79 +/- 0.23. However, the AUCT for this amount of time (T=12 days) was not significantly different from the AUC∞, which was estimated from the single dose administration. As a very weakly basic and also lipophilic compound with low aqueous solubility, cinnarizine is able to cross the blood brain barrier by simple diffusion. It is because of this property that it is able to exert its effects on cerebral blood flow in the brain.
Bioavailability of orally administered cinnarizine is typically low and variable due to high incidence of degradation. However, it has been found that when administered intravenously in lipid emulsion, better pharmacokinetics and tissue distribution were achieved. The lipid emulsion administration had a higher AUC and lower clearance than the solution form, which meant that there was an increased bioavailability of cinnarizine, allowing for an improved therapeutic effect. Plasma pharmacokinetics of cinnarizine administered intravenously follows a three-compartment model first with a fast distribution phase, followed by a slower distribution phase, and ending with a very slow elimination. The Vss (steady state apparent volume of distribution) for lipid emulsion administration was 2x lower (6.871+/- 1.432 L/kg) than that of cinnarizine given in solution (14.018 +/- 5.598 L/kg) and it was found that significantly less cinnarizine was taken up into the lung and brain in the lipid emulsion condition. This is significant because it would reduce the likelihood of toxic side effects in the central nervous system.
Cinnarizine is classified as a selective antagonist of T-type voltage-operated calcium ion channels, because its binding blocks the channels and keeps them inert. It has a Ki (inhibitory constant) value of 22nM. It is also known to have antihistaminic, antiserotoninergic and antidopaminergic effects, binding to H1 histamine receptors, and dopaminergic (D2) receptors. The IC50 (half-maximal inhibitory concentration) of cinnarizine for smooth muscle contraction inhibition is 60mM and it has been shown that this drug preferentially binds to its target calcium channels when they are in an open, as opposed to closed conformation. In treatment of nausea and motion sickness it was previously hypothesized that cinnarizine exerts its effects by inhibiting the calcium currents in voltage gated channels in type II vestibular hair cells within the inner ear. However, more recent evidence supports the idea that at pharmacologically relevant levels (0.3µM–0.5µM), cinnarizine is not lessening vestibular vertigo by blocking calcium channels, but rather by inhibiting potassium (K+) currents that are activated by heightened hydrostatic pressure on the hair cells. It is true that cinnarizine does abolish calcium currents in vestibular hair cells as well; it is just that this only occurs at higher concentrations of drug (3µM). The inhibition of these currents works to lessen the vertigo and motion-induced nausea by dampening the over-reactivity of the vestibular hair cells, which send information about balance and motion to the brain.
|Action of cinnarizine||Target of action|
|Calcium ion channel antagonist||T-type calcium channels|
After administration, cinnarizine is completely metabolized within the body and the metabolites are eliminated by one third in the urine and two thirds in solid waste.
- Terland O, Flatmark T (June 1999). "Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles". Neuropharmacology. 38 (6): 879–82. doi:10.1016/s0028-3908(98)00233-0. PMID 10465691. S2CID 40061724.
- Nicholson AN, Stone BM, Turner C, Mills SL (June 2002). "Central effects of cinnarizine: restricted use in aircrew". Aviation, Space, and Environmental Medicine. 73 (6): 570–4. PMID 12056673.
- Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ (1991). "Cinnarizine for prevention of nausea and vomiting during platin chemotherapy". Acta Oncologica. 30 (6): 731–4. doi:10.3109/02841869109092448. PMID 1958394.
- Pianese CP, Hidalgo LO, González RH, Madrid CE, Ponce JE, Ramírez AM, Morán LM, Arenas JE, Rubio AT, Uribe JO, Abiuso J, Hanuch E, Alegría J, Volpi C, Flaskamp R, Sanjuán AP, Gómez JM, Hernández J, Pedraza A, Quijano D, Martínez C, Castañeda JR, Guerra OJ, F GV (May 2002). "New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study". Otology & Neurotology. 23 (3): 357–63. doi:10.1097/00129492-200205000-00023. PMID 11981396. S2CID 23282116.
- Arab SF, Düwel P, Jüngling E, Westhofen M, Lückhoff A (June 2004). "Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (6): 570–5. doi:10.1007/s00210-004-0936-3. PMID 15138660. S2CID 27410833.
- "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2011" (PDF). WHO. Retrieved 2015-03-12.
- Lucertini M, Mirante N, Casagrande M, Trivelloni P, Lugli V (May 2007). "The effect of cinnarizine and cocculus indicus on simulator sickness". Physiology & Behavior. 91 (1): 180–90. doi:10.1016/j.physbeh.2007.02.008. PMID 17434541. S2CID 45239084.
- Deka, C.V.R. (2006). "Role of Cinnarizine in Peripheral Vertigo". Vertigo Viewpoint. 4 (1): 2–4.
- Ganança MM, Caovilla HH, Munhoz MS, Ganança CF, da Silva ML, Serafini F, Ganança FF (2007). "Optimizing the pharmacological component of integrated balance therapy". Brazilian Journal of Otorhinolaryngology. 73 (1): 12–8. doi:10.1016/s1808-8694(15)31116-2. PMID 17505593.
- Haasler T, Homann G, Duong Dinh TA, Jüngling E, Westhofen M, Lückhoff A (December 2009). "Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells". Naunyn-Schmiedeberg's Archives of Pharmacology. 380 (6): 531–8. doi:10.1007/s00210-009-0463-3. PMID 19830405. S2CID 1845935.
- Yates BJ, Miller AD, Lucot JB (November 1998). "Physiological basis and pharmacology of motion sickness: an update". Brain Research Bulletin. 47 (5): 395–406. doi:10.1016/s0361-9230(98)00092-6. PMID 10052567. S2CID 23368593.
- "Stugeron 15". NHS. Archived from the original on 2012-05-07. Retrieved 2012-10-21.
- Gil A, Nachum Z, Tal D, Shupak A (2012). "A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study". Clinical Neuropharmacology. 35 (1): 37–9. doi:10.1097/WNF.0b013e31823dc125. PMID 22139622. S2CID 24196565.
- Saletu B, Grünberger J (1980). "Antihypoxidotic and nootropic drugs: proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations". Progress in Neuro-Psychopharmacology. 4 (4–5): 469–89. doi:10.1016/0364-7722(80)90017-x. PMID 7012879.
- Towse G (September 1980). "Cinnarizine--a labyrinthine sedative". The Journal of Laryngology and Otology. 94 (9): 1009–15. doi:10.1017/s0022215100089787. PMID 7000939.
- RomPharm. Pyracin (piractam 400 mg and cinnarizine 25 mg). 2008 [cited 2012 10/20].
- Teive HA, Troiano AR, Germiniani FM, Werneck LC (June 2004). "Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis". Parkinsonism & Related Disorders. 10 (4): 243–5. doi:10.1016/j.parkreldis.2003.12.004. PMID 15120099.
- Poignet H, Beaughard M, Lecoin G, Massingham R (October 1989). "Functional, behavioral, and histological changes induced by transient global cerebral ischemia in rats: effects of cinnarizine and flunarizine". Journal of Cerebral Blood Flow and Metabolism. 9 (5): 646–54. doi:10.1038/jcbfm.1989.92. PMID 2777934.
- Arieli R, Shupak A, Shachal B, Shenedrey A, Ertracht O, Rashkovan G (1999). "Effect of the anti-motion-sickness medication cinnarizine on central nervous system oxygen toxicity". Undersea & Hyperbaric Medicine. 26 (2): 105–9. PMID 10372430.
- Emanuel MB, Chamberlain JA, Whiting S, Rigden BG, Craven AH (February 1979). "Cinnarizine in the treatment of chronic asthma". British Journal of Clinical Pharmacology. 7 (2): 189–95. doi:10.1111/j.1365-2125.1979.tb00920.x. PMC 1429430. PMID 367414.
- Tosoni C, Lodi-Rizzini F, Cinquini M, Pasolini G, Venturini M, Sinico RA, Calzavara-Pinton P (March 2009). "A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients". Clinical and Experimental Dermatology. 34 (2): 166–70. doi:10.1111/j.1365-2230.2008.02891.x. PMID 18681869. S2CID 26074302.
- Rissardo JP, Caprara AL (December 2020). "Cinnarizine- and flunarizine-associated movement disorder: a literature review". The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 56 (1): 61. doi:10.1186/s41983-020-00197-w. ISSN 1687-8329.
- Kariya S, Isozaki S, Masubuchi Y, Suzuki T, Narimatsu S (November 1995). "Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine". Biochemical Pharmacology. 50 (10): 1645–50. doi:10.1016/0006-2952(95)02057-8. PMID 7503767.
- Fabiani G, Pastro PC, Froehner C (September 2004). "Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine". Arquivos de Neuro-Psiquiatria. 62 (3B): 784–8. doi:10.1590/S0004-282X2004000500008. PMID 15476069.
- Serrano A, Menéndez J, Casarejos MJ, Solano RM, Gallego E, Sánchez M, et al. (August 2005). "Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice". Neuropharmacology. 49 (2): 208–219. doi:10.1016/j.neuropharm.2005.03.003. PMID 15993444. S2CID 41909759.
- Turner D, Lurie Y, Finkelstein Y, Schmid T, Gopher A, Kleid D, Bentur Y (May 2006). "Pediatric cinnarizine overdose and toxicokinetics" (PDF). Pediatrics. 117 (5): e1067–9. CiteSeerX 10.1.1.566.5819. doi:10.1542/peds.2005-2059. PMID 16636115. S2CID 11045925.
- Spagnoli A, Tognoni G (July 1983). "'Cerebroactive' drugs. Clinical pharmacology and therapeutic role in cerebrovascular disorders". Drugs. 26 (1): 44–69. doi:10.2165/00003495-198326010-00003. PMID 6349963. S2CID 46985958.
- Castañeda-Hernández G, Vargas-Alvarado Y, Aguirre F, Flores-Murrieta FJ (May 1993). "Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers". Arzneimittel-Forschung. 43 (5): 539–42. PMID 8328998.
- Nowacka-Krukowska H, Rakowska M, Neubart K, Kobylińska M (2007). "High-performance liquid chromatographic assay for cinnarizine in human plasma". Acta Poloniae Pharmaceutica. 64 (5): 407–11. PMID 18540159.
- Kornhuber J, Henkel AW, Groemer TW, Städtler S, Welzel O, Tripal P, Rotter A, Bleich S, Trapp S (July 2010). "Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system". Journal of Cellular Physiology. 224 (1): 152–64. doi:10.1002/jcp.22112. PMID 20301195. S2CID 25095807.
- Kalava, B.S.; Muzeyyen, Demirel; Yasemin, Yazan (2005). "Physicochemical characterization and dissolution properties of cinnarizine solid dispersions". J. Pharm. Sci. (in Turkish). 2 (2): 51–62.
- Emanuel MB (July 1979). "Specific calcium antagonists in the treatment of peripheral vascular disease". Angiology. 30 (7): 454–69. doi:10.1177/000331977903000704. PMID 464337. S2CID 38239037.
- Shi S, Chen H, Lin X, Tang X (January 2010). "Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion". International Journal of Pharmaceutics. 383 (1–2): 264–70. doi:10.1016/j.ijpharm.2009.09.025. PMID 19770029.
- Klein M, Musacchio JM (October 1989). "High affinity dextromethorphan binding sites in guinea pig brain. Effect of sigma ligands and other agents". The Journal of Pharmacology and Experimental Therapeutics. 251 (1): 207–15. PMID 2477524.
- Silver PJ, Dachiw J, Ambrose JM, Pinto PB (September 1985). "Effects of the calcium antagonists perhexiline and cinnarizine on vascular and cardiac contractile protein function". The Journal of Pharmacology and Experimental Therapeutics. 234 (3): 629–35. PMID 3162016.
- López MG, Moro MA, Castillo CF, Artalejo CR, García AG (March 1989). "Variable, voltage-dependent, blocking effects of nitrendipine, verapamil, diltiazem, cinnarizine and cadmium on adrenomedullary secretion". British Journal of Pharmacology. 96 (3): 725–31. doi:10.1111/j.1476-5381.1989.tb11874.x. PMC 1854390. PMID 2720300.
- Pukhal'skaya TG, Kolosova OA, Men'shikov MY, Vein AM (July 2000). "Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine". Bulletin of Experimental Biology and Medicine. 130 (7): 633–5. doi:10.1007/BF02682090. PMID 11140571. S2CID 2173191.